Tarsier pharma will be participating at the Oppenheimer Rare & Orphan Disease Summit taking place virtually on May 21, 2021. The event will feature presentations and 1×1 meetings with a select group of companies in the Rare & Orphan Disease arena. Investors will have the opportunity to meet with management teams to discuss in detail key therapeutic programs in development and recent corporate updates. Dr. Daphne Haim-Langford, Founder and CEO of Tarsier, will present a corporate update about the Company’s current developments including TRS01 for uveitic glaucoma and TRS02 for back-of-the-eye inflammatory diseases. The session will be followed by a Q&A discussion, after which the Company will hold 1X1 meetings. Investors interested in participating or meeting with Tarsier are welcome to contact their Oppenheimer’s representative. For more details, please see the event’s link here.